A Look Into Healthcare Sector Value Stocks

What is a Value Stock? A value stock traditionally has a lower price when compared to stock prices…

What is a Value Stock?

A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued.

Below is a list of notable value stocks in the healthcare sector:

  1. First Wave BioPharma (NASDAQ:FWBI) – P/E: 0.0
  2. Exicure (NASDAQ:XCUR) – P/E: 0.36
  3. Aprea Therapeutics (NASDAQ:APRE) – P/E: 0.14
  4. Organon (NYSE:OGN) – P/E: 5.07
  5. Prenetics Global (NASDAQ:PRE) – P/E: 0.3

First Wave BioPharma has reported Q2 earnings per share at $-1.89, which has decreased by 3.85% compared to Q1, which was -1.82. Most recently, Exicure reported earnings per share at $-0.68, whereas in Q1 earnings per share sat at $-0.7. Aprea Therapeutics saw an increase in earnings per share from -1.34 in Q1 to $-0.87 now. Most recently, Organon reported earnings per share at $1.31, whereas in Q1 earnings per share sat at $1.11. Most recently, the company reported a dividend yield of 5.14%, which has increased by 0.52% from last quarter’s yield of 4.62%.

Most recently, Prenetics Global reported earnings per share at $-0.05, whereas in Q1 earnings per share sat at $-0.04. The company’s most recent dividend yield sits at 1.99%, which has decreased by 0.02% from 2.01% last quarter.

The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.

Total
0
Shares
Related Posts
Read More

Lixte Biotechnology Holdings Reports That Its Lead Clinical Compound, LB-100, Can Kill Cancer Cells Through Hyper-Stimulation Of Cell Proliferation Signals In Pre-Clinical Models; Shares Halted On Circuit Breaker To The Upside

--THE STUDY ESTABLISHES A NOVEL CONCEPT OF "TUMOR SUPPRESSIVE DRUG RESISTANCE"   --THE COMBINATION OF LB-100 WITH INHIBITORS OF CELLULAR STRESS RESPONSE MODULATORS WAS HIGHLY EFFECTIVE IN

LIXT